Abstract
Bilateral intra-accumbens 6-OHDA (2 micrograms in the presence of DMI and tranylcypromine, 14th postoperative day) enhanced the climbing responses of mice to apomorphine and 2-(N,N-dipropyl)amino-5,6-dihydroxytetralin causing parallel shifts of the normal log dose-response curves to the left. The enhancement of the apomorphine response was shown to be dependent on the dose of 6-OHDA, 0.5 micrograms being threshold and 2 micrograms maximum. Increased climbing was apparent by the 5th postoperative day, maximum by the 10th day, and was then maintained throughout the experimental period (6-8 weeks). 0.25-2 micrograms intra-accumbens 6-OHDA caused dose-related decreases in the dopamine content of mesolimbic areas (nucleus accumbens and tuberculum olfactorium) without causing significant changes in mesolimbic noradrenaline or striatal dopamine. In the absence of DMI/tranylcypromine, 2 and 4 micrograms 6-OHDA also decreased mesolimbic noradrenaline and striatal dopamine content. 16 micrograms 6-OHDA injected into the striatum (after DMI/tranylcypromine) decreased the striatal dopamine content by 85% (without altering mesolimbic dopamine or noradrenaline content) but this treatment failed to modify apomorphine climbing (2nd-12th postop...Continue Reading
References
Jul 1, 1978·European Journal of Pharmacology·B CostallV Nohria
Apr 1, 1979·The Journal of Pharmacy and Pharmacology·B CostallV Nohria
Jun 15, 1979·European Journal of Pharmacology·B CostallV Nohria
Aug 7, 1978·Life Sciences·J W Kebabian
Feb 21, 1977·European Journal of Pharmacology·J F Marshall, U Ungerstedt
Nov 1, 1976·European Journal of Pharmacology·B Costall, R J Naylor
Oct 20, 1976·Psychopharmacology·P ProtaisJ C Schwartz
Aug 5, 1977·Science·I CreeseS H Snyder
Apr 1, 1976·European Journal of Pharmacology·A J PuechJ R Boissier
Aug 1, 1976·Journal of Neurochemistry·P C Waldmeier, L Maître
Apr 1, 1965·British Journal of Pharmacology and Chemotherapy·R LAVERTY, D F SHARMAN
Dec 1, 1964·International Journal of Neuropharmacology·C C CHANG
Citations
Jan 1, 1981·Psychopharmacology·B CostallV Nohria
Jan 1, 1989·Psychopharmacology·D Duterte-Boucher, J Costentin
Feb 1, 1984·Naunyn-Schmiedeberg's Archives of Pharmacology·P ProtaisJ C Schwartz
Jan 1, 1991·Journal of Neural Transmission. General Section·S K Bhattacharya, A P Sen
Jan 1, 1990·Psychopharmacology·C SchremmerT Ott
Sep 1, 1995·Psychopharmacology·S CabibS Puglisi-Allegra
Apr 23, 1984·Brain Research·S CabibA Oliverio
Oct 1, 1990·Brain Research·E SundströmT Archer
Dec 10, 1985·European Journal of Pharmacology·J R Martin, A E Takemori
Sep 1, 1982·Neuropharmacology·A KuruvillaN J Uretsky
Apr 1, 1987·Steroids·Y K FungR W Brueggemeier
Oct 1, 1982·Pharmacology, Biochemistry, and Behavior·Y K FungD R Grassman
Jan 1, 1986·Pharmacology, Biochemistry, and Behavior·Y K FungN J Uretsky
Nov 1, 1987·Alcohol·H C BeckerC L Randall
Apr 1, 1997·Physiology & Behavior·S Cabib, N Bonaventura
Aug 2, 2002·Pharmacology, Biochemistry, and Behavior·Jun-ichi KarasawaKazutoshi Horikomi
Jan 1, 1988·Neuroscience and Biobehavioral Reviews·C PinskyR Bose
Sep 1, 1985·Behavioral and Neural Biology·S CabibA Oliverio
May 10, 2001·Schizophrenia Research·T RasmussenF P Bymaster
Apr 29, 2000·Schizophrenia Research·H E ShannonA Fink-Jensen
Nov 1, 1981·Neuropharmacology·J P GonzalezP S Spencer
Apr 18, 2009·Behavioural Brain Research·Susanne KootGiovanni Laviola
Feb 16, 1988·Brain Research·S CabibS Puglisi-Allegra
May 1, 1982·The Journal of Pharmacy and Pharmacology·J P GonzalezR D Sewell